SK Biopharmaceuticals, twoXAR collaborate to develop treatments for NSCLC
As per terms of the deal, twoXAR will apply its AI discovery technology to identify a set of initial candidates to treat lung cancer through novel biological mechanisms
German company Merck has introduced the first single-use reactor specifically designed for the production of antibody-drug conjugates (ADCs).
The research collaboration is part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program. The Centers for Disease Control and Prevention (CDC) estimates that 6-7 million people in
iPSCs can be derived from adult human tissue cells yet share the developmental potentials of embryonic stem cells. Currently Japan has 6 ongoing clinical trials utilizing this technology,